Effectiveness of hepatitis C antiviral treatment in attended patients from the outpatient pharmacy consultation

Authors

  • José Miguel Sotoca Momblona Servicio de Farmacia. Hospital Clínic de Barcelona
  • Montserrat Rodriguez-Reyes Servicio de Farmacia. Hospital Clínic de Barcelona.
  • Neus Pagès-Puigdemont Servicio de Farmacia. Hospital Clínic de Barcelona.
  • Concepción Bartres-Viñas Servicio de Hepatología. Hospital Clínic de Barcelona
  • Sergio Rodriguez-Tajes Servicio de Hepatología. Hospital Clínic de Barcelona
  • Sabela Lens-García Servicio de Hepatología. Hospital Clínic de Barcelona
  • Zoe Mariño-Mendez Servicio de Hepatología. Hospital Clínic de Barcelona

Keywords:

pharmaceutical care, hepatitis C, effectiveness

Abstract

Objective: To determine the effectiveness of the treatment of chronic hepatitis C determined as the sustained viral response at 12 weeks (SVR12) after the end of treatment with direct-acting antiviral drugs (DAA) (glecaprevir/pibrentasvir, sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir and grazoprevir/elbasvir) in attended patients from the outpatient pharmacy consultation.

Method: a retrospective study that includes patients attended by pharmacists who started treatment between December 1, 2017 and May 31, 2018. Demographic data, disease, adherence and treatment consultations were recorded (interactions, adverse effects and others).

Results: Two hundred and five patients were included, with different hepatitis C genotypes, fibrosisstates and morbidity levels. Effectiveness was 99.5%, similar to that of clinical trials.Conclusions: These results resemble those obtained in pharmacy consultations in the United States,operating for more than ten years.

Downloads

Download data is not yet available.

References

Asselah T, Marcellin P, Schinazi RF. Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure? Liver International. 2018;38(Suppl. 1):7–13

Crystal D, Dwayne D, Essex W, Deming P, Qualls C.R, Mera J. Hepatitis C treatment outcomes in a pharmacist-managed clinic in a rural tribal health system. Hepatology 2017; Volume 66, Issue 1, Supplement, S1-S876

Smith JP, Dong MH, Kaunitz JD. Evaluation of a pharmacist-managed hepatitis C care clinic. Am J Health Syst Pharm. 2007;64(6):632-6

Naidjate SS, Zullo AR, Dapaah-Afriyie R, et al. Comparative effectiveness of pharmacist care delivery models for hepatitis C clinics. Am J Health Syst Pharm. 2019;76(10):646-653

Casanovas Guitart C, Ballester Zanuy MI, Mendoza García de Paredes MD, Furió Domínguez P, Aguas Lluch, A, Boixadera Vendrell M. Clasificación de los usuarios incluidos en gestión de casos por grupos de morbilidad ajustados (GMA). I Congreso Internacional, Nacional y II Autonómico de enfermeras gestoras de casos (2015).

Downloads

Published

2020-03-20

How to Cite

1.
Sotoca Momblona JM, Rodriguez-Reyes M, Pagès-Puigdemont N, Bartres-Viñas C, Rodriguez-Tajes S, Lens-García S, Mariño-Mendez Z. Effectiveness of hepatitis C antiviral treatment in attended patients from the outpatient pharmacy consultation. Ars Pharm [Internet]. 2020 Mar. 20 [cited 2024 Jul. 22];61(1):45-7. Available from: https://revistaseug.ugr.es/index.php/ars/article/view/11672

Issue

Vol. 61 No. 1 (2020)

Section

Original Articles

License

Copyright (c) 2020 José Miguel Sotoca Momblona, Montserrat Rodriguez-Reyes, Neus Pagès-Puigdemont, Concepción Bartres-Viñas, Sergio Rodriguez-Tajes, Sabela Lens-García, Zoe Mariño-Mendez

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:

  1. The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.

b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.

c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).